Abstract:Introduction Approximately 75% of women aged between 45 years and 55 years suffer from symptoms of menopause. Untreated hot flashes have many downstream effects including but not limited to fatigue, low energy, memory complaints, lowered libido, sexual dysfunction and may even be linked to increased cardiovascular disease. While the gold standard for effective treatment is hormonal therapy, many women (especially those with a family history of breast cancer) may decline their use due to concerns regarding efficacy and safety. Lack of sensitivity training and level of comfort to disclose menopausal symptoms is often a significant barrier to effective treatment. Dose optimization, close surveillance of efficacy of hormone utilization is essential to maintain patient compliance. Objective Menopausal hot flashes are associated with a variety of downstream sexual complaints including lowered libido. This retrospective study was done to assess if optimal treatment of hot flashes with hormones and over the counter products would have a downstream effect on concurrent reported sexual complaints. Methods A retrospective review of a random convenience sample was conducted to assess women who presented with complaints of hot flashes. Concurrent associated symptoms were also reported. Treatment interventions and symptom resolution was evaluated. Data was collected and stored in private HIPPA protected database. Results A random convenience sample (n=56) from the HerMD centers (Cincinnati and Kentucky) was assessed for women (mean age 51.3; range 30-73) who presented with complaints of hot flashes. Associated symptoms included: brain fog/memory complaints (66%); sleep disturbances including insomnia (59%), decreased libido (49%), weight management concerns (38%), vaginal dryness (31%) and dyspareunia (14%). A family history of breast cancer was present in 18% of the sample. Treatment included: behavioral intervention counseling (100%), over the counter supplements n=2, (3.5%) and systemic hormonal therapy n=54 (96.5%) and over the counter recommendations (100%). All patients (100%) with a family history of breast cancer received hormonal therapy. Overall, 96% of patients responded to their intervention with self-reported improvement in hot flashes, and improvement in dyspareunia, vaginal dryness and improved libido at scheduled follow up visits. Patients had multiple office/telehealth visits to ensure dose optimization, efficacy of symptom resolution and ensure no treatment emergent adverse effects. There were n=3 (5%) reported adverse effects (minimal vaginal spotting) yet no patients discontinued treatment Conclusions Hot flashes are associated with a variety of sexual complaints including but not limited to decreased libido (49%), vaginal dryness (31%) and dyspareunia (14%). Optimal treatment of hot flashes will have downstream efficacy with FSD complaints. At HerMD, HCP have internal continuing menopausal medical education which includes standardized clinical algorithms, bibliotherapy, article data base, 1-1 didactic education/supervision and preceptorships with national menopausal experts. Systemic hormones will help with vaginal dryness and dyspareunia. HerMD advocates close clinical surveillance with treatment efficacy and safety review which allows for interventions to be modified henceforth allow for outcome optimization and enhance compliance. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Michael Krychman is a consultant for exeltis pharmaceuticals, Astellas, Uberlube and CEEK.

Effect of estrogen metabolic enzyme cytochrome P450 gene polymorphism on susceptibility of hot flashes in perimenopause women

Differential Factors Associated with Hot Flashes in Chinese Perimenopausal and Postmenopausal Women

Correlation of Polymorphism in Estrogen Metabolizing Genes CYP17 and Estrogen Exposure and Its Relation with Breast Cancer Susceptibility

Effect of the Levels of Serum Gonadal Hormone and Plasma Calcitonin Gene-Related Peptide on the Hot Flushes Symptom of Perimenopausal Women

Association of genetic polymorphisms in CYP19A1 and blood levels of sex hormones among postmenopausal Chinese women.

The relationship between hot flashes and fatty acid binding protein 2 in postmenopausal women

Correlation Between Polymorphism of Estrogen Receptor Α Gene and Anxiety and Depression During Menopause

Serum exomiR content in perimenopausal women with hot flashes-effects of hormone replacement therapy

The role of estrogen receptor gene polymorphisms in menopausal symptoms and estradiol levels in perimenopausal women – Findings from the Swiss Perimenopause Study

Single nucleotide polymorphism of estrogen metabolizing genes CYP17、CYP19 and breast cancer susceptibility

CYP19 A1 gene polymorphism and polycystic ovarian syndrome

Effect of Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) Supplementation on Hot Flashes in Menopausal Women: A Randomized, Double - Blind, Placebo- Controlled Clinical Trial

(134) Effective Treatment Of Menopausal Hot Flashes Improves Downstream Female Sexual Complaint

Relation among Single Nucleotide Polymorphism in Estrogen Metablolizing Genes CYP17, COMT and Endometrial Adenocarcinoma Risk

Association of single nucleotide polymorphisms of cytochrome P450 enzymes with experience of vasomotor, vaginal and musculoskeletal symptoms among breast cancer patients: a systematic review

[Study on the Relationship Between Polymorphisms of Genes (CYP17, CYP19 and SULT1A1) and Susceptibility to Breast Cancer in Chinese Women].

Relationship between susceptibility of polycystic ovary syndrome and gene polymorphism of microsomal epoxide hydrolase in chinese women

Case-control Study for Estrogen Metabolic Enzyme Gene SNPs and Susceptibility to Uterine Leiomyoma

ATL: A Meta-analysis

Polymorphisms in the CYP19A1 (Aromatase) Gene and Endometrial Cancer Risk in Chinese Women

The study of the impact of genetic polymorphism of aromatase (CYP19) enzyme and the susceptibility to polycystic ovary syndrome (575.5)